Research Brought to Life

Clinical trials are the most important tool we have for improving the survival of patients with cancer. You should discuss with your doctor whether a clinical trial is available and appropriate for you.

Reset
Reset
Reset

SC291-101 (Closed)

SC291-101 SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers. Disease Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia SummaryThis is…
Read More

BGB-11417-108

BGB-11417-108 The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies. DiseaseChronic Lymphocytic Leukemia CLL SummaryThis study…
Read More

MYDAS-T

MYDAS-T Advancing treatment therapies in Myelodysplasia DiseaseMyelodysplasia SummaryTraditionally, combination therapy has not proven to be effective in Myelodysplasia (MDS) given the increased toxicity of drugs used in combination with standard…
Read More

CML14 (ASCENDANCE)

CML14 (ASCENDANCE) A study to assess efficacy of combination therapy with asciminib plus low dose dasatinib in newly diagnosed chronic phase Chronic Myeloid Leukaemia (CML) with high risk genetics DiseaseChronic…
Read More

ALLG NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry This study contains no assessments above those that would be offered as standard of care. Information from clinical investigations (including results…
Read More

AMLM26/T3 INTERCEPT

AMLM26/T3 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – Low-dose cytarabine (LDAC) + Venetoclax DiseaseAcute…
Read More

AMLM26 INTERCEPT

AMLM26 INTERCEPT MRD A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – The Master Protocol DiseaseAcute Myeloid…
Read More

AMLM26/T1 INTERCEPT

AMLM26/T1 INTERCEPT AMLM26/T1 INTERCEPT: A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – Gilteritinib+ Venetoclax DiseaseAcute Myeloid…
Read More

SOUNDTRACK-B

AZD0486 as Monotherapy in Participants With Relapsed/​Refractory (R/​R) B-cell NHL (SOUNDTRACK-B) This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy…
Read More

RIDDLE-M-X

Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The RIDDLE-M-X trial DiseaseMultiple Myeloma…
Read More

PRIMAVERA (D9971C00001)

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of…
Read More

BGB-16673-104

BGB-16673-104 A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies. DiseaseB-cell Malignancy Relapsed Cancer Refractory Cancer B-cell…
Read More

SNDX5613

A Study of Revumenib in R/​R Leukemias Including Those With an MLL/​KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in…
Read More

NHL39 POLABEAR

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (POLAR BEAR) R-MINI-CHOP Versus R-MINI-CHP in…
Read More

TITANium

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/​R B-Cell Malignancies. (TITANium) This is a Phase I/II study…
Read More

LBS-007

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias A Phase 1/2, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of…
Read More

JBI-802-102

Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects with Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) with Thrombocytosis. Study to Assess Safety…
Read More

APOLLO AP30CP01

A Study to Investigate APL-4098 Alone and/​or in Combination With Azacitidine in R/​R AML and High-Risk MDS A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-4098…
Read More

KRT-232-115

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS) A Phase 2/3 Randomized, Controlled, Open-Label Study of…
Read More

BGB-11417-203

BGB-11417-203 This study will evaluate the safety and efficacy of the BCL2 inhibitor BGB-11417 (sonrotoclax) in participants with relapsed/refractory Waldenström’s Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult…
Read More

SOUNDTRACK-F1

A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1) This…
Read More

MajesTEC-7

MajesTEC-7 A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide,…
Read More

CCTL019E2301 (LEDA)

A Randomized, Open-label, Multi-center Phase III Trial Comparing Tisagenlecleucel to Standard of Care in Adult Participants With Relapsed or Refractory Follicular Lymphoma (FL). DiseaseFollicular Lymphoma (FL) SummaryThe purpose of this…
Novartis
Read More

ZE46-0134-002

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukaemia. DiseaseFLT3 mutated Relapsed or…
Read More

TrAVeRse

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) TrAVeRse is a multicentre, open-label, randomised, Phase II study of AVR in treatment naïve MCL participants. The…
Read More

DR-0201-ONC-001

A Multicenter, Multiple Expansion Cohort, Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma This is a…
Read More

D7230C00001

D7230C00001 This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants…
Read More

87801493LYM1001

87801493LYM1001 A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer DiseaseLymphoma, Non-Hodgkin SummaryThe purpose of this study is to characterize safety and…
Read More

INDEPENDENCE (Closed)

INDEPENDENCE – NO LONGER RECRUITING An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red…
Read More

BGB-21447

BGB-21447 Phase 1 Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies DiseaseRelapsed Non-Hodgkin Lymphoma Refractory Non-Hodgkin Lymphoma Relapsed Chronic Lymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Relapsed Follicular Lymphoma…
Read More

AMLM26/T4 INTERCEPT

AMLM26/T4 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – SNDX5613 DiseaseAcute Myeloid Leukaemia SummaryThe ALLG…
Read More

BGB11417-301

BGB11417-301 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) DiseaseCLL SummaryThe main objective of this study is to compare…
Read More

SKYGLO (Closed)

SKYGLO – NO LONGER RECRUITING An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma DiseaseLarge…
Read More

ISB 2001-101

ISB 2001-101 Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma DiseaseRelapsed/Refractory Multiple Myeloma SummaryThis study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of…
Read More

GOlDiLOX

GOlDiLOX A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. DiseaseMantle Cell Lymphoma Mantle Cell Lymphoma Refractory SummaryBrief Summary: The goal…
Read More

IKS03-01

IKS03-01 IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas DiseaseB-cell Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Follicular Lymphoma Mantle Cell Lymphoma B-cell Lymphoma SummaryThis first-in-human study will evaluate…
Read More

APTIVATE (Closed)

APTIVATE – NO LONGER RECRUITING A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or…
Read More

DREAMM-20

DREAMM-20 A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in…
Read More

IMpress_001 (Closed)

IMpress_001 – NO LONGER RECRUITING Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) DiseaseMyelodysplastic Syndromes Acute Myeloid Leukemia SummaryThe purpose of this study…
Read More

CTX112 (CRSP-ONC-006)

CTX112 A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies DiseaseB-cell Lymphoma Non-Hodgkin Lymphoma B-cell Malignancy Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Follicular…
Read More

M20-621 (Closed)

M20-621 – NO LONGER RECRUITING A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed…
Read More

MagnetisMM-5 (Closed)

MagnetisMM-5 – NO LONGER RECRUITING Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/​Refractory Multiple Myeloma (MAGNETISMM-5) DiseaseMultiple Myeloma SummaryBrief…
Read More

PRT2527-02

PRT2527-02 A Study of PRT2527 in Participants With Relapsed/Refractory Hematologic Malignancies DiseaseAggressive B-Cell Non-Hodgkin’s Lymphoma Aggressive B-Cell NHL Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Mantle Cell Lymphoma (MCL) Richter’s Syndrome SummaryThis…
Read More

DR-01-ONC-001 (Closed)

DR-01-ONC-001 – NO LONGER RECRUITING A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas DiseaseLGLL – Large Granular Lymphocytic Leukemia Primary Cutaneous T-Cell Lymphoma –…
Read More

LOXO-BTK-20019 (Closed)

LOXO-BTK-20019 – NO LONGER RECRUITING Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) DiseaseLymphoma, Mantle-Cell SummaryThis is a Phase 3…
Read More

80948543LYM1001

80948543LYM1001 A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) DiseaseLymphoma, Non-Hodgkin Leukemia, Lymphocytic,…
Read More

BGB-11417-103

BGB-11417-103 A Study of BGB-11417 in Participants With Myeloid Malignancies DiseaseAcute Myeloid Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasm SummaryThe study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and…
Read More

M20-638 (Closed)

M20-638 – NO LONGER RECRUITING Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE…
Read More

MajesTEC-9

MajesTEC-9 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9) DiseaseRelapsed or Refractory Multiple Myeloma SummaryThe…
Read More

SLN124-004

SLN124-004 Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera DiseasePolycythemia Vera SummaryThis is a Phase 1/2,…
Read More

D8231C00001 (Closed)

D8231C00001 – NO LONGER RECRUITING AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL DiseaseRelapsed/Refractory Peripheral T-cell Lymphoma Relapsed/Refractory Classical Hodgkins Lymphoma…
Read More

MAJIC (Closed)

MAJIC – NO LONGER RECRUITING A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic…
Read More

DZ2022B0002

DZ2022B0002 A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) DiseaseNon-Hodgkin Lymphoma…
Read More

AMLM26/T5 INTERCEPT

AMLM26/T5 INTERCEPT A multi-arm trial for patients with acute myeloid leukaemia investigating new treatments which target early relapse and changes in disease characteristics – MBG453 OR MBG453 and Azacitidine DiseaseLeukaemia…
Read More

BLOCK PCNSL (NHL32)

BLOCK PCNSL (NHL32) An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma DiseaseLymphoma (non Hodgkin’s lymphoma) SummaryThe purpose of this study is…
Read More

SUCCESSOR-1 (CA057-001)

SUCCESSOR-1 (CA057-001) A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma…
Read More

ASTX660-03 (Closed)

ASTX660-03 – NO LONGER RECRUITING A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) DiseaseRelapsed/Refractory Peripheral T-cell…
Read More

BELLWAVE

Bellwave (MK-1026-003) A Phase 2 Study to Evaluate the Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies DiseaseHematologic Malignancies SummaryThe purpose of this study is to evaluate…
Read More

NHL35: ALLG-PACIFIC

NHL35: ALLG-PACIFIC An open label phase 2 study of Pembrolizumab And Chemo-Immunotherapy as FIrst-line therapy for primary mediastinal B-Cell lymphoma DiseaseB-Cell Lymphoma Summary open label phase II study of R-CHOP…
Read More

Zentalis ZN-d5-003 (Closed)

Zentalis ZN-d5-003 – NO LONGER RECRUITING This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis. Disease Amyloidosis…
Read More

SNDX-5613-0700 (Closed)

SNDX-5613-0700 – NO LONGER RECRUITING A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Disease Acute Myeloid Leukemia Acute Lymphoblastic Leukemia…
Read More

GB5121-2101: STAR-CNS (Closed)

GB5121-2101: STAR-CNS – NO LONGER RECRUITING The STAR CNS trial is a 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, to assess the safety,…
Read More

EZH-302

EZH-302 A Phase 1b/3 Double Blind Randomized, Active-Controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma DiseaseRelapsed/Refractory Follicular…
Read More

ESCALADE (Closed)

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)
Read More

COALITION (Closed)

A multicentre, parallel arm, open-label trial of frontline R-CHOP/Pola-RCHP and glofitamab in younger, higher risk patients with…
Read More

LOXO-BTK-20022 (Closed)

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously…
Read More

BGB-16673-101

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients…
Read More

STARGLO (Closed)

STARGLO – NO LONGER RECRUITING Starglo is a phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in…
Read More

DREAMM 8 (Closed)

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in…
Read More

FRONTMIND (Closed)

A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide…
Read More

Epcoritamab (GCT3013-02)

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in…
Read More

TARMAC (Closed)

A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of…
Read More

64264681LYM1002 (Closed)

A Phase 1b, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64264681 in Combination with JNJ-67856633…
Read More

D8230C00002 (Closed)

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in…
Read More

AMLM25

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly Acute…
Read More

IGM-2323 (Closed)

A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in…
Read More

ENHANCE (Closed)

A Randomized, Double Blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine plus Placebo in…
Read More

NHL33 (Closed)

NHL33 – NO LONGER RECRUITING An ALLG Window Study of Acalabrutinib plus Rituximab followed by Cytarabine, Oxaliplatin, Dexamethasone and Rutixumab (R-DHAOx) + Autologous Stem Cell Transplant (ASCT) in newly diagnosed…
Read More

DREAMM 3 (Closed)

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin…
Read More

AMLM22/D2

The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to…
Read More

ITHACA (Closed)

A Phase 3 Randomized, Open Label, Multicenter Study of Isatuximab (SAR650984) in Combination With Lenalidomide and Dexamethasone…
Read More

GCT-3013-01 (Closed)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Read More

BGB-3111-113 (Closed)

A Drug–Drug Interaction Study of Zanubrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancies
Read More

MALT-1 (Closed)

A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of…
Read More

UNITY-NHL (Closed)

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab +…
Read More

GO29781 (Closed)

An open-label, multicenter, phase I/IB trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as…
Read More

FORMA (Closed)

A Phase 1/2 study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of FT-2102 with or without azacitidine…
Read More

PLIMATH (Closed)

A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (PLIMATH)
Read More

GMI-1271-301 (Closed)

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy…
Read More

DREAMM6 (Closed)

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide…
Read More

ACE-CL-311 (Closed)

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in…
Read More

LOXO-BTK-18001 (Closed)

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma…
Read More

LEVERAGE (Closed)

Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment Naïve Follicular Lymphoma
Read More

ASSURE (Closed)

ASSURE is a Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib in Subjects with Chronic Lymphocytic Leukaemia.
Read More

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature…
Read More

Clinical Trial FAQ’s